ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2206

Data on Treatment from Brazilian Fibromyalgia Patients Registry (EpiFibro)

José E. Martinez1,2, Marcelo C. Rezende1,3, Eduardo Paiva1,4, Daniel Pollak1,5, Milton Helfenstein Jr1,6, Jose Roberto Provenza1,7, Aline Ranzolin1,8, Luiz Severiano Ribeiro1,9, Eduardo J. R. Souza1,10, Roberto E Heymann1,11 and Marcos Renato Assis1,12, 1Brazilian Society of Rheumatology, São Paulo, Brazil, 2Rheumatology, Pontificia Universidade Católica de São Paulo, Sorocaba, Brazil, 3Santa Casa de Campo Grande, Campo Grande, Brazil, 4Rheumatology, Universidade Federal do Parana, Curitiba Parana, Brazil, 5Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, 6RUA JOAO DE LACERDA SOARES, 90, Universidade Federal de São Paulo, Sao Paulo, Brazil, 7Rheumatology, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, 8Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, 9Instituto de Previdência dos Servidores do Estado de Minas Gerais, Belo Horizonte, Brazil, 10Santa Casa de Belo Horizonte, Belo Horizonte, Brazil, 11Universidade Federal de São Paulo, São Paulo, Brazil, 12Rheumatology, Faculdade de Medicina de Marilia, Marilia, Brazil

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fibromyalgia, non-pharmacologic intervention, pharmacotherapy, registry and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Brazilian registry on fibromyalgia syndrome (EpiFibro) included 810 patients who satisfied the American College of Rheumatology Classification Criteria for Fibromyalgia (ACR1990) at the time of diagnosis. Objectives – 1. Describe treatment modalities for Brazilian Patients; 2. Describe treatment measures in each of the modalities.

Methods: – A transversal study on a multicenter cohort of Brazilian Fibromyalgia patients. All patients fulfilled at the data entry the American College of Rheumatology Classification Criteria for Fibromyalgia. The analysis was made through descriptive statistical technique (frequency and standard deviation).  

Results: Three hundred and forty two (342) entries were excluded for having incomplete forms at the treatment modalities. In relation of the therapeutic modalities, it was observed: sixty-six (66) patients are taking only medications and no non-pharmacological therapy; four hundred and fifty five (455) patients are taking some medicines; three hundred and three (303) patients are receiving some kind of health education; two hundred and six (206) patients are practicing exercises and ninety seven (97) are getting some kind of other non-pharmacological measures. The most frequent combination of modalities is medicine, health education and exercises (89). The only 2 drugs approved for fibromyalgia in Brazil are duloxetine (57 patients in use) and pregabalin (11 patients in use). Other medications with proved efficacy by literature have also being prescribed off label, such as amitriptyline (115), venlafaxine (17), fluoxetine (49), cyclobenzaprine (77), tramadol (30) and gabapentin (11). The most used medication associations are: fluoxetine and amitriptyline (88), fluoxetine and cyclobenzaprine (14), amitriptyline and cyclobenzaprine (7), tramadol and paracetamol (23). Other associations were also reported: pregabalin and duloxetine (2), pregabalin and amitriptyline (3), pregabalin and fluoxetine (5), gabapentin and duloxetine (1), gabapentin and amitriptyline (1). There were also prescribed triple associations. In relation to exercises, 108 patients practice aerobics, 26 stretching exercises and 2 strengthening exercises. The most frequent combination is aerobics and stretching exercises (48). The non-pharmacological measures most used are heated swimming pool exercises (17), relaxing techniques (10), acupuncture (10), psychotherapy (9), massage (6) and tender point infiltration (6). It has been also mentioned hypnosis, homeopathy and biofeedback.

Conclusion: The majority of Brazilian fibromyalgia patients are treated by a combination of pharmacological and non-pharmacological measures. It is prescribed approved medications for fibromyalgia, but the most prescribed drug is amitriptyline off label, probably for economic reasons. The most prescribed medicine combination is fluoxetine and amitriptyline. The most practiced exercises are the aerobics modalities and the most non-pharmacological measures are health education and exercises in heated swimming pool.


Disclosure: J. E. Martinez, None; M. C. Rezende, None; E. Paiva, None; D. Pollak, None; M. Helfenstein Jr, None; J. R. Provenza, None; A. Ranzolin, None; L. S. Ribeiro, None; E. J. R. Souza, None; R. E. Heymann, None; M. R. Assis, None.

To cite this abstract in AMA style:

Martinez JE, Rezende MC, Paiva E, Pollak D, Helfenstein Jr M, Provenza JR, Ranzolin A, Ribeiro LS, Souza EJR, Heymann RE, Assis MR. Data on Treatment from Brazilian Fibromyalgia Patients Registry (EpiFibro) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/data-on-treatment-from-brazilian-fibromyalgia-patients-registry-epifibro/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/data-on-treatment-from-brazilian-fibromyalgia-patients-registry-epifibro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology